Phase II Clinical Trial of Allodepleted T Cell Immunotherapy (ATIR101) Post-Transplant Results in Decreased Transplant-Related Mortality and Improved Survival in Acute Leukemia Patients Undergoing T-Depleted Haploidentical Stem Cell Transplantation